

R&D Alliance

Enhancement of the R&D Pipeline through In-Licensing and Alliance Activities

In-licensing and alliance activities as important supplemental measures to enhance Takeda's R&D pipeline; we will continue to actively employ these strategies. We have been developing a system to

promote close relationships with alliance partners and efficiently expand our activities at a global level. As part of this system we have appointed staff exclusively in charge of alliance activities in Japan, the U.S. and Europe. These initiatives are seeing steady results as shown below.

Advances in In-Licensing and Alliance Activities from April 2008 Onwards

Partners	Activities
Sucampo Pharmaceuticals, Inc. (U.S.A.)	In April 2008, the U.S. Food and Drug Administration (FDA) approved Sucampo Pharmaceuticals' supplemental New Drug Application (sNDA) for <i>Amitiza</i> —a treatment for chronic idiopathic constipation—in order to treat irritable bowel syndrome with constipation.
Alnylam Pharmaceuticals, Inc. (U.S.A.)	In May 2008, Alnylam and Takeda entered into an agreement for a non-exclusive license for Alnylam's RNAi therapeutics platform technology in the fields of oncology and metabolic diseases, as well as collaborative research based on this project.
Amgen Inc. (U.S.A.)	In June 2008, Takeda submitted a New Drug Application to the Ministry of Health, Labour and Welfare in Japan for panitumumab, an anti-cancer agent in-licensed from Amgen, for the treatment of patients with progressed and/or relapsed colorectal cancer. In November 2008, based on the results of a safety data review conducted by an independent Data Monitoring Committee (DMC), Takeda and Amgen agreed to suspend temporarily the enrollment of patients with squamous and non-squamous non-small cell lung cancer (NSCLC) into Phase III clinical trials of AMG706, an anti-cancer agent in-licensed from Amgen. In February 2009, following a further review, the DMC recommended that the trial resume the enrollment of non-squamous NSCLC patients.
CanBas Co., Ltd. (Japan)	In November 2008, Takeda started Phase II clinical trials in the United States of CBP501, an anti-cancer agent in-licensed from CanBas for the treatment of malignant pleural mesothelioma. Phase II clinical trials with CBP501 for the treatment of NSCLC began in June 2009.
Alizyme plc (U.K.)	In December 2008, Takeda commenced Phase III clinical trials in Japan for ATL-962, a compound in-licensed from Alizyme for treating obesity.
XOMA Ltd. (U.S.A.)	In February 2009, building on a joint R&D agreement originally concluded in November 2006 for antibody-based pharmaceuticals, Takeda and XOMA agreed to expand the existing collaboration to provide Takeda with access to a suite of R&D technologies related to antibody-based pharmaceuticals together with integrated information and data management systems.
Teijin Pharma Limited (Japan)	In February 2009, Takeda received FDA marketing approval for TMX-67 (U.S. brand name: <i>ULORIC</i>), a treatment for hyperuricemia in patients with gout that Takeda in-licensed from Teijin Pharma. TPNA launched the drug in the U.S. in March 2009.
Novartis AG (Switzerland)	In May 2009, Takeda concluded an in-licensing agreement with Novartis for a vaccine to prevent infections caused by <i>Haemophilus influenzae</i> type B (Hib vaccine).

As of July 31, 2009

Partner's Voice

Takeda is a Japanese company that has enjoyed considerable international success. In 1999, we entered into a licensing agreement with Takeda's U.S. subsidiary TPNA for *ULORIC* (generic name: febuxostat), a treatment for hyperuricemia in patients with gout. I have since been deeply impressed with Takeda's superb development capabilities and their attitude in constantly rising to the challenge of overcoming numerous obstacles. All these efforts have now paid off, and I am delighted that the product was launched in the U.S. in the spring of 2009. TPNA has been extremely active promoting *ULORIC* since the launch, and I am confident that the value of this product will be maximized going forward. This success has inspired us to work towards forging a deeper and stronger alliance with Takeda.

Osamu Nishikawa, President, Teijin Pharma Limited



Note: Established in 2002, Teijin Pharma Limited is the core company of Teijin Group's medical and pharmaceuticals business. Its main businesses are in pharmaceuticals and delivery of home healthcare services. It specializes in the development of innovative products and services in the three fields of bone and joint diseases, respiratory disease, and metabolic and cardiovascular disease.